Abstract
Research data suggest an association between antipsychotic‐induced hyperprolactinemia and higher risk of breast cancer (Rahman et al., 2022; also, see “Breast cancer risk with antipsychotic use linked to prolactin levels;” https://doi.org/10.1002/pu.30853). This is likely secondary to the anti‐dopaminergic properties of antipsychotics, especially those of first‐generation agents.